Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arena And Vivus Take Divergent Paths To Respond To Obesity Setbacks

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

To little surprise, FDA has issued “complete responses” for two of the main competitors racing to develop new obesity drugs. While both drug candidates were knocked down on their first pass over by the agency, the similarities stop there.

You may also be interested in...



Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin

The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.

Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin

The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.

Vivus' Qnexa Gets "Complete Response" Letter From FDA

FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel